Peripheral T-cell lymphoma, not otherwise specified

Kunal Kishor Jha¹, Suresh K. Gupta², Harpreet Saluja³, Nuwadatta Subedi⁴

¹Department of Psychiatry, All India Institute of Medical Sciences, Patna, Bihar, India. ²Department of Internal Medicine, Forest Glen Medical Center, Silver Spring Maryland, MD, USA. ³Department of Internal Medicine, Royal College of Surgeons in Ireland and Medical University of Bahrain, Southern Governorate, Bahrain. ⁴Department of Forensic Medicine, Gandaki Medical College, Pokhara, Nepal

ABSTRACT

The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct clinical features define this disease. Patients can experience night sweats, fever, lymphadenopathy, weight loss, splenomegaly, and/or skin changes. Common laboratory tests reveal that patients have anemia, thrombocytosis, lymphocytosis, eosinophilia, hypogammaglobulinemia, or increased lactate dehydrogenase. In this case study, a patient presented with massive lymphadenopathy and right lower limb swelling, which he developed over 6 weeks. A tissue biopsy and supporting investigations confirmed the diagnosis of PTCL, NOS.

Keywords: CHOP regimen, lymphoma, peripheral T-cell lymphoma not otherwise specified, pralatrexate

INTRODUCTION

Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) comprises a common, extranodal, and nodal T-cell lymphomas subgroup. These lymphomas are not characterized by any known clinicopathological criteria. In Western countries, PTCL, NOS is the most widespread subtype of PTCL, affecting about 30% of PTCL patients and 4% of overall non-Hodgkin lymphomas (NHLs).[1-9] The World Health Organization and the European Organization for Research and Treatment of Cancer have grouped PTCL, NOS in a class of primary skin lymphomas having a diverse clinical presentation. Such lymphomas demonstrate a higher frequency in middle-aged males, with a male: female ratio of 2.5:1.[9]

CASE REPORT

An 80-year-old Italian male with a history of hypertension, type II diabetes mellitus, osteoarthritis, and glaucoma presented with a complaint of right groin pain that persisted for 6 weeks. He had a mass in the right groin. He had no fever, anorexia or weight loss, and no other lumps in other parts of the body. His level of energy was good. There was no history of alcohol and smoking. There was no history of similar illness in the family.

We palpated an 11 cm × 6 cm solid mass in the right groin. Distended veins could be seen over the mass. A swelling was also present on the right lower limb, along with pitting edema up to the popliteal fossa. All vital systems were otherwise healthy. He was already taking glipizide 5 mg OD, pravastatin 20 mg OD, glucosamine and chondroitin sulfate BID, and multivitamins.

We ordered a complete blood count (CBC), comprehensive metabolic panel (CMP), and computed tomography (CT) scan for the abdomen and pelvis. His CBC, CMP, and peripheral smear were normal. CT of the abdomen and pelvis showed a right inguinal lymph node mass measuring up to 11.3 cm × 6.3 cm anteroposteriorly and transversely extending up to 13 cm in length [Figure 1]. There was a 2.4 cm cystic or necrotic component in the inferior lateral position of the mass [Figure 2]. Fine-needle aspiration cytology (FNAC) was scheduled. CT-guided FNAC of the mass revealed numerous small to mid-sized atypical lymphoid

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Jha KK, Gupta SK, Saluja H, Subedi N. Peripheral T-cell lymphoma, not otherwise specified. J Family Med Prim Care 2017;6:427-30.
cells, which were consistent with NHL. To confirm NHL, a core biopsy was performed. It showed diffuse effacement of nodular architecture by small to intermediate-sized lymphocytes with moderate cytologic atypia [Figure 3].

The immune cell infiltrates were CD3 [Figure 4] and CD30 being positive. Within the mass, 57% of infiltrates stained strongly for CD2 and CD3. The alpha and beta T-cell receptor stainings were positive while the gamma delta receptor staining was negative. An immunohistochemical stain for ALK1 was negative. Epstein–Barr virus staining was negative. The combination of morphological and immunophenotypical findings was most consistent with PTCL, NOS.

**Treatment**

After the diagnosis of PTCL, NOS, the patient was sent to an oncologist. Serum protein electrophoresis, erythrocyte sedimentation rate, and positron emission tomography scan were normal. CHOP regimen total of six cycles every 3 weeks was prescribed. After the first cycle, his limb became less swollen, and he reported a significant improvement in his symptoms. He took a total of four cycles of the CHOP regimen and he no longer followed up. Two years later, he returned with the complaint of heart palpitation and breathlessness. On investigations, we found cytopenia. We did a bone marrow biopsy to check for relapse, and we found bone marrow metastasis. After confirmation of relapse, we treated the patient with pralatrexate.

**Discussion**

The PTCLs are aggressive tumors and comprise about 15% of all adult NHL.[1,7] In the United States, from 1992 to 2006, there was an increase in the incidence of PTCL from 0.1 cases per 100,000 patients to about 0.4 cases per 100,000 patients.[8] The disease usually develops in adults and the average age of occurrence is 60 years at the time of diagnosis.[9] The associated risk factors of PTCL, NOS are still not known although immune-suppressing drugs, Epstein–Barr infection, smoking, chemicals like pesticides, and solvents exposure have been linked to the disease.[10,11]

The PTCL, NOS is characterized by symptoms of generalized lymphadenopathy and rare extranodal disease.[9,10,12] Extranodal...
sites mostly involved are the gastrointestinal tract and skin.[13,14]

There is no particular morphological aspect of this tumor. PTCL, NOS is usually diagnosed by a biopsy of the tumor tissue or a lymph node. However, to establish the tumor's T-cell origin, assessment of the immunophenotype is needed, and it is done either by flow cytometry or immunohistochemistry. Immunohistochemistry is reliable because large lymphoid cells are available for examination, whereas in flow cytometry, samples are sometimes lost or disrupted during processing.[10,11] PTCL, NOS contains mixtures of small, intermediate, and large atypical cells.[16,17] When genotypically investigated, antigens linked to T-cells are found to be expressed although with no consistent pattern (CD2+/−, CD3+/−, CD7−/+ , CD5+/−). PTCL, NOS does not stain positive for B-cell antigens.[17,18] In the majority of cases, a loss of mature T-cell antigens (one or more) occurs, including CD7 or CD5. Immunophenotype of PTCL, NOS is highly variable but always expresses T-cell antigens (such as CD3, CD2, CD7, and CD5).

Clinically, it had been found that PTCL, NOS is an aggressive disease, which often results in relapse.[3,10,19-21] Our patient also suffered a relapse of the symptoms, and he was then given pralatrexate. He responded well to the medication. The most important elements in the treatment of peripheral T-cell lymphomas are early recognition and appropriate management. While PTCL, NOS carries a significant mortality rate, an early diagnosis of PTCL, NOS and compliance with medications may save a patient's life.

**Summary**

Peripheral T-cell lymphoma can present with massive lymphadenopathy, which can present as limb swelling. The clinical course of PTCL, NOS is aggressive, and if remission is achieved, relapses are frequent. Pralatrexate and CHOP regimen have been used for the treatment of PTCL with variable success.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-5032.

2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.

3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.

4. Abramson JS, Feldman T, Kroll-Desrosiers AR, Mufly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy. Ann Oncol 2014;25:2211-7.

5. Ellin F, Landsström J, Jerkeman M, Rolander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. Blood 2014;124:1570-7.

6. Rezania D, Sokol L, Cuing HD. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control 2007;14:112-23.

7. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90.

8. Abouyabas AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099-107.

9. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.

10. Weisenburger DD, Savage KJ, Harris NL, Gascogne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402-8.

11. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): A review. Hematol Oncol 2008;26:8-20.

12. Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol 2004;127:140-54.

13. Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992;141:1361-71.

14. Gonzalez CL, Medeiros LJ, Baziad RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.

15. Bekkenk MW, Vermeer MH, Jansen PM, van Marion AM, Canninga-van Dijk MR, Kuin PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: Analysis of prognostic factors in a group of 82 patients. Blood 2003;102:2213-9.

16. Suchi T, Lennert K, Tu LY, Kikuchi M, Sato E, Stansfeld AG, et al. Histopathology and immunohistochemistry of peripheral T cell lymphomas: A proposal for their classification. J Clin Pathol 1987;40:995-1015.

17. Weiss LM, Crabtree GS, Rouse RV, Warnke RA. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 1985;118:316-24.

18. Borowitz MJ, Reichert TA, Brynes RK, Cousar JB, Whitcomb CC, Collins RD, et al. The phenotypic diversity of peripheral T-cell lymphomas: The Southeastern Cancer Study Group experience. Hum Pathol 1986;17:567-74.

19. Weisenburger DD, Linder J, Armitage JO. Peripheral T-cell lymphoma: A clinicopathologic study of 42 cases. Hematol Oncol 1987;5:175-87.

20. Coiffier B, Brousse N, Peuchmair M, Berger F, Gisselbrecht C,
Bryon PA, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990;1:45-50.
21. Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M, et al. Peripheral T-cell lymphoma. Cancer 1989;63:158-63.